SecBot SecBot
8-K ·Filed Aug 26, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 8/10
Horizonimmediate Processed2mo ago SEC0001193125-26-366931
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

This approval converts RVMD from a pure-play clinical-stage biotech to a commercial-stage company with a priced product. Monitor initial prescription volumes, payer coverage decisions, and any competitor RAS inhibitor developments. The high market cap already reflects substantial optimism, but the data and pricing support a multi-billion peak sales opportunity if RASONQUE delivers meaningful survival benefit.

DirectionBullish
Confidencehigh
Horizonimmediate

daraxonrasib

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3 (completed with positive results) / pre-NDA
Time to market
NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
Next catalyst
None dated

What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$215.44
T+0 close · Aug 26, 2026 · via day close
Latest settled
−7.23%
T+20 · $199.86 · next T+60 in 2d
Vs SPY
−7.46%
α at T+20
Latest observation
−8.84%
T+56 · FF3 residual α
  1. T+0 · Aug 26 $215.44entry
  2. T+1 · 3mo ago +2.65%α +2.00% · $221.15
  3. T+5 · 3mo ago −2.88%α −2.76% · $209.23
  4. T+20 · 8w ago −7.23%α −7.46% · $199.86
  5. T+57 · todayOpen
  6. T+60 · in 2d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines announced FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma on August 26, 2026, based on Phase 3 RASolute 302 data. The oral therapy is now available in the U.S. with a wholesale acquisition cost of $39,800 per 30-day supply. This is a transformative milestone for the company, converting its lead pipeline asset to a commercial product in a large unmet-need indication.

Key Facts

  • FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent therapy is not an option.
  • Approval based on Phase 3 RASolute 302 trial vs. investigator's choice chemotherapy.
  • Once-daily oral tablets immediately available for prescribing in the U.S.
  • Wholesale acquisition cost is $39,800 for a 30-day supply at the recommended dose.
  • Company is Revolution Medicines, Inc. (ticker: RVMD), a late-stage biotech with a $45.3B market cap.

Financial Impact

First approved product, pricing at ~$39,800/month. For a pancreatic cancer indication with estimated ~60,000 new U.S. cases/year (of which ~80% are metastatic), even capturing 5-10% of the eligible second-line-plus population could represent annualized revenue in the hundreds of millions to low billions, subject to label uptake, competition, and reimbursement.

RevenueProduct sales growthPipeline valuation

Risk Factors

  • Competition from other RAS pathway inhibitors (e.g., Amgen's Lumakras, Mirati's Krazati, or future pan-RAS drugs) could limit market share.
  • Reimbursement and formulary access for a high-priced oral oncolytic may be slow in the second-line+ pancreatic setting.
  • Pancreatic adenocarcinoma is a difficult-to-treat cancer; real-world survival data may not fully replicate trial results.
  • Stock already at $45B market cap, priced for substantial commercial success, leaving limited upside if uptake disappoints.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-366931
Document: 0001193125-26-366931-index.html0001193125-26-366931
Document: 0001193125-26-366931.txt0001193125-26-366931

US Market Status

Market Closed · Opens in 8h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 26, 2026